File downloaded on 2026-11-08
Source URL: https://medicines.health.europa.eu/veterinary/en/600000000558

ProteqFlu-Te (--) - Suspension for injection

Authorised

- Canarypox virus, strain vCP3011, expressing haemagglutinin gene of Influenza A virus subtype H3N8 (A/equine/Richmond/1/2007), Live
- Canarypox virus, strain vCP2242, expressing haemagglutinin gene of Influenza A virus subtype H3N8 (A/equine/Ohio/03), Live
- Clostridium tetani, toxoid

Product identification

Medicine name:
ProteqFlu-Te (--) - Suspension for injection

Active substance:
Canarypox virus, strain vCP3011, expressing haemagglutinin gene of Influenza A virus subtype H3N8 (A/equine/Richmond/1/2007), Live

Canarypox virus, strain vCP2242, expressing haemagglutinin gene of Influenza A virus subtype H3N8 (A/equine/Ohio/03), Live

Clostridium tetani, toxoid

Target species:
Horse

Route of administration:
Intramuscular use

Product details

Active substance and strength:

Canarypox virus, strain vCP3011, expressing haemagglutinin gene of Influenza A virus subtype H3N8 (A/equine/Richmond/1/2007), Live

Presentation_strength:vCP3011 ≥ $10^{5.3}$ FAID50 Reference:Hse Index:0

Canarypox virus, strain vCP2242, expressing haemagglutinin gene of Influenza A virus subtype H3N8 (A/equine/Ohio/03), Live

Presentation_strength:vCP 2242 ≥ $10^{5.3}$ FAID50 Reference:Hse Index:1

Clostridium tetani, toxoid

Presentation_strength:≥ 30 IU/ml Reference:Hse Index:2

Pharmaceutical form:

Suspension for injection

Withdrawal period by route of administration:

Intramuscular use:

- **Horse**
  - Not applicable. 0 day Zero days

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI05AI01

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

---

Authorisation status:

Valid

Authorised in:

Austria , Belgium , Bulgaria , Croatia , Cyprus , Czechia , Denmark , Estonia , Finland , France , Germany , Greece , Hungary , Iceland , Ireland , Italy , Latvia , Liechtenstein , Lithuania , Luxembourg , Malta , Netherlands , Norway , Poland , Portugal , Romania , Slovakia , Slovenia , Spain , Sweden , United Kingdom (Northern Ireland)

Available in:
Austria , Belgium , Czechia , France , Germany , Luxembourg , Slovakia , Spain

Package description:
Packaging:Vial (glass), Package_size:10 vials, Content:1 ml

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Complete application (stand-alone) - Council Directive 81/851/EEC

Marketing authorisation holder:
Boehringer Ingelheim Vetmedica GmbH

Marketing authorisation date:
6/03/2003

Manufacturing sites for batch release:
Boehringer Ingelheim Animal Health France

Responsible authority:
European Commission

Authorisation number:
This information is not available for this product.

Date of authorisation status change:
13/02/2006

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)
Published on: 14/03/2026
Download

ema-puar-proteqflu-te-v-074-par-en.pdf

ema-puar-proteqflu-te-v-074-var-ii-0017-en.pdf